Benzinga | Mar 10, 2021 07:10AM EST

Adicet Bio Initiates First-In-Human Phase 1 Trial Of ADI-001 For Treatment Of B Cell Non-Hodgkin's Lymphoma

MENLO PARK, Calif. and BOSTON, Mass., March 10, 2021 /PRNewswire/ -- Adicet Bio, Inc. (NASDAQ:ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that it has initiated its First-in-Human Phase I clinical trial evaluating ADI-001 for the treatment of B cell non-Hodgkin's lymphoma (NHL). ADI-001 is an investigational first-in-class allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor (CAR) targeting CD20, engineered to potentially enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.